The discovery of 071031B, a novel serotonin and noradrenaline reuptake inhibitor.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Neuroscience Letters

• Publication date

  2013-06-07

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.neulet.2013.02.076PMID 23570736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor.

  2013cited by this paper
• Vilazodone for the Treatment of Major Depressive Disorder

  2012cited by this paper
• Pharmacodynamic and toxicological evaluation of duloxetine

  2010cited by this paper
• Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action

  2009cited by this paper
• Progress in the development of early-onset antidepressants

  2008cited by this paper
• Antidepressant-like effects of the ethanolic extract of Xiaobuxin-Tang, a traditional Chinese herbal prescription in animal models of depression.

  2007cited by this paper
• Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor

  2006cited by this paper
• Case history: the discovery of fluoxetine hydrochloride (Prozac).

  2005cited by this paper
• The Discovery of Fluoxetine Hydrochloride (Prozac)

  2005cited by this paper
• The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.

  2005cited by this paper
• Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

  2004cited by this paper
• The tail suspension test: A new method for screening antidepressants in mice

  2004cited by this paper
• Animal models of depression: are there any?

  2003cited by this paper
• The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

  2003cited by this paper
• Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders

  2003cited by this paper
• Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test

  1998cited by this paper
• Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity

  1998cited by this paper
• [Protective effects of antioxidants on experimental liver injuries].

  1990cited by this paper
• Behavioral despair in mice: a primary screening test for antidepressants.

  1977cited by this paper
• L-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders.

  1974cited by this paper
• Statistics In Biology.

  1971cited by this paper
• The catecholamine hypothesis of affective disorders: a review of supporting evidence.

  1965cited by this paper
• Tests for pathophysiologic identification and classification of psychoses.

  1958cited by this paper
• The history of marsilid.

  1958cited by this paper
• [Treatment of depressive states with an iminodibenzyl derivative (G 22355)].

  1957cited by this paper

• Drug-Drug Interactions of Antidepressant Ammoxetine Mediated by CYP2D6 and MATE1: From In Vitro Mechanistic Investigations to In Vivo Validation

  2026cites this paper
• Efficacy and Safety of Ammoxetine in Major Depressive Disorder

  2025cites this paper
• In vitro, in vivo, and in silico approaches for evaluating the preclinical DMPK profiles of ammoxetine, a novel chiral serotonin and norepinephrine reuptake inhibitor

  2024cites this paper
• Role of microglia in diabetic neuropathic pain

  2024cites this paper
• High-content imaging of human hepatic spheroids for researching the mechanism of duloxetine-induced hepatotoxicity

  2022cites this paper
• First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study.

  2021cites this paper
• A hypothesis of monoamine (5-HT) - Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery.

  2020cites this paper
• Network-based drug repositioning: A novel strategy for discovering potential antidepressants and their mode of action.

  2018cites this paper
• Ammoxetine attenuates diabetic neuropathic pain through inhibiting microglial activation and neuroinflammation in the spinal cord

  2018cites this paper
• Advances in Drug Discovery and Development in Geriatric Psychiatry

  2018cites this paper
• Chiral analysis of ammuxetine enantiomers in dog plasma using online SPE/liquid chromatography with tandem mass spectrometric detection after precolumn chiral derivatization.

  2017cites this paper
• Testing Neurotransmitters for Toxicity with a Luminescent Biosensor: Implications for Microbial Endocrinology

  2017cites this paper
• Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors

  2017cites this paper
• Treating Adult Women With Depression Through Videoconferencing

  2017cites this paper
• A hierarchical screening approach to enantiomeric separation.

  2017cites this paper
• Effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor, on monoamine system in mice and rats.

  2016cites this paper
• Evaluation of the analgesic effects of ammoxetine, a novel potent serotonin and norepinephrine reuptake inhibitor

  2016cites this paper
• Anxiolytic effects of GLYX-13 in animal models of posttraumatic stress disorder-like behavior

  2016cites this paper
• Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders.

  2016cites this paper
• Antidepressant‐like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor

  2016cites this paper
• Stress-based animal models of depression: Do we actually know what we are doing?

  2016cites this paper
• Emergence of Chinese Drug Discovery Research

  2015cites this paper
• The discovery of Yuanzhi-1, a triterpenoid saponin derived from the traditional Chinese medicine, has antidepressant-like activity.

  2014cites this paper